Carlyle, Hellman & Friedman-backed PPD could hit $8bn valuation through sale, IPO process

US buyout houses Carlyle and Hellman & Friedman are said to be prepping for a sale or IPO of research business Pharmaceutical Product Development which could value it at up to $8bn.